Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35758368/
Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge. No randomized clinical trials...
Relevance: Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge. No randomized clinical trials have examined the efficacy of trastuzumab in this setting. This prospective observational study aimed to...
Comparative efficacy trials in inflammatory bowel disease: current and future implications for practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35762693/
Head-to-head clinical trials are critically important to advance the field of IBD. Comparative efficacy trials are slow and expensive to conduct, may not be broadly generalizable, and are not powered...
Summary: Head-to-head clinical trials are critically important to advance the field of IBD. Comparative efficacy trials are slow and expensive to conduct, may not be broadly generalizable, and are not powered for safety events or other relevant outcomes. Alternative approaches to comparative effectiveness such as network meta-analysis and well...
Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy
Source : https://www.futuremedicine.com/doi/10.2217/fon-2022-0365
A common side effect of chemotherapy is the unintended killing of important immune cells that can fight infections. Because of this effect, patients with cancer who are treated with chemotherapy...
Conclusion/Relevance: A common side effect of chemotherapy is the unintended killing of important immune cells that can fight infections. Because of this effect, patients with cancer who are treated with chemotherapy can experience a serious, sometimes deadly condition called febrile neutropenia (FN). Pegfilgrastim is a medication that is...
Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35755898/
In oncology practices across the United States, biosimilars-highly similar versions of licensed, innovator (reference) biological medicines-are currently emerging as more affordable therapeutic options. Only after a rigorous product development program,...
Conclusion/Relevance: Advanced practitioners are often tasked with building the confidence of colleagues and patients who may be unfamiliar with biosimilars, skeptical about integrating them, or have yet to consider mAb biosimilars as a viable and more sustainable cancer treatment option. With this responsibility comes a number of challenges...
Meaning: The high efficacy warrants further randomized evaluation of the addition of a programmed cell death 1 inhibitor to standard trastuzumab and chemotherapy in ERBB2-positive EGA. Chemotherapy should not be replaced by ipilimumab in an unselected ERBB2-positive population.